Drugs / ORE1001
ORE1001
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT01039597 | Dec 2009 → Jun 2011 | ulcerative colitis | Ore Pharmaceuticals, Inc. | Unknown | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ORE1001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01039597 ↗ |
| Known as | GL1001 | ChEMBL registry synonym — accepted as the source's own label CHEMBL429844 ↗ |
| Known as | MLN-4760 | ChEMBL registry synonym — accepted as the source's own label CHEMBL429844 ↗ |
| Known as | ORE-1001 FREE ACID | ChEMBL registry synonym — accepted as the source's own label CHEMBL429844 ↗ |
| Modality | Small molecule | — CHEMBL429844 ↗ |
| Route | Oral | “administered as capsules by mouth” NCT01039597 ↗ |